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Abstract
Androgenic alopecia (AGA), also known as male and female pattern baldness, is the loss of hair on the scalp for both men and women.
The onset of hair loss for men suffering from this condition can occur as early as their teens or early 20s. Symptoms include a receding hairline and gradual disappearance of hair at the vertex and frontal scalp.When women have female pattern baldness (FPB),
their hair doesn’t appear thinning until they reach their 40s or older. Generally, women experience a thinning of the hair over the
whole scalp, with the most extensive hair loss at the vertex.The FDA-approved hair loss treatments finasteride and minoxidil topical
are often capable of halting and even reversing hair loss when examined over the course of many treatments. Other medications
that have shown effectiveness in treating hair loss have yet to be approved by the FDA, either due to a lack of evidence showing their
effectiveness or because of concerns about side effects.The main disadvantage of using hair loss drugs is having to take them continuously in order to maintain their benefits and the intake of finasteride causing sexual functional disorders. For those who want to
avoid the risk of sexual function disorders, there are other alternatives to these two drugs, such as low-level light therapy, platelet-rich
plasma therapy (PRP), and hair transplant. Even though there is no cure for hair loss, this study discusses a number of treatments that
are invasive or non-invasive, and the patient should consult with their doctor before beginning any treatment.
Abbreviations
AGA: androgenetic alopecia
AR: androgen receptors
DHT: dihydrotestosterone
FDA: Food and Drug Administration
FPB: female pattern baldness
KCZ: ketoconazole
LLLT: low-level laser therapy
MAA: male androgenetic alopecia
MPB: male pattern baldness
MPHL: male pattern hair loss
MS: minoxidil solution
OTC: over-the-counter
PDGF: platelet-derived growth factor
PG: propylene glycol
PRP: platelet-rich plasma
5AR: 5-alpha-reductase/5α−reductase
Introduction
Many people experience hair loss, medically known as alopecia. Hair loss comes in a variety of forms. Androgenetic
alopecia (AGA), also known as male pattern baldness
(MPB), is characterized by a receding hairline (making
an “M” shape), thinning at the crown of the head, and is
caused by hormones. By the age of 50, roughly 30-50% of
men experience this type of hair loss (Rafi & Katz, 2011).
The trend of hair loss in women differs from that of
males. Women’s hair thins all over the head, but the hairline does not recede like the men. In women, androgenetic alopecia rarely results in complete baldness (Medline
Plus, 2015). Alopecia has few physical side effects, but it
can cause psychological problems, such as excessive levels
of anxiety, depression, and can greatly affect self-esteem

and self-image (Cranwell & Sinclair, 2016). Males are typically thought to suffer from androgenetic alopecia more
often than females (Feinstein, 2020). This study will determine whether lost hair can be regrown and review
the pharmacologic treatments of androgenetic alopecia.
Hormonal hair loss is the most common and well-studied
kind, therefore, androgenetic alopecia will be the subject
of this research.
Objectives
• To understand what androgenetic alopecia is
• The causes of androgenetic alopecia
• Discuss medicinal treatments for hair loss.
• Explain the clinical studies and chemical aspects of prescribed drug use among patients struggling with male
and female pattern baldness.
• Explore the probable health complications with prescribed drug intake by the patient with androgenetic
alopecia.
• Discuss alternative methods to manage hair loss, like
platelet-rich plasma, therapy (PRP), low-level light therapy, and hair transplant.
Methods
This comprehensive review was conducted using multiple
databases available through Google Scholar, Medline Plus,
Mayo Clinic, and WebMD.Additional resources were available
via the website of the National Center for Biotechnology
(NCBI). Additionally, filters were applied to retrieve relevant
articles.The search for articles on the topic revealed articles
describing the treatments used for hair loss and the adverse
effects that come with taking them.
Signs and Symptoms
How does one know if they are experiencing androgenetic alopecia? On average, people lose 50 to 100 hairs
every day. This frequently goes undetected because new
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hair grows at the same time. One of the symptoms of alopecia is when the hair that has fallen out is not replaced
by new hair (Mayo Clinic Staff, 2020). The affected areas
progress from highly pigmented, thick, terminal hairs to
thinner, shorter, indeterminate hairs (Feinstein, 2020).
The average male or female patient notices a thinning of
their scalp hair as they age (Shapiro, 1998). The most common form of hair loss is male androgenetic alopecia (MAA),
which affects 30-50% of men by 50 years of age (Cranwell
& Sinclair, 2016). Usually, after puberty, some men notice
scalp hair loss or a receding hairline. As opposed to men,
women usually begin experiencing symptoms in their 50s
or 60s.Women may experience androgenetic alopecia ear-

different stages for males depicted in figure 1.With female
pattern baldness, thinning occurs on the top and crown
of the head (Figure 2).Women commonly experience this
thinning as a widening of the midline hairline that leaves
their front hairline untouched (Feinstein, 2020).
The image shows the normal amount of hair on a
woman in stage 1. In stage 2 the image shows signs of hair
loss by the widening of the central part. By stage 3 there
is widening of the central part of the scalp and there is
loss of volume lateral to the part line. Stage 4 shows the
development of a bald spot anteriorly. The hair loss at
Stage 5 is advanced (Sinclair, et al., 2015).

Figure 1:The
Norwood- Hamilton
Scale of male
androgenetic alopecia
(Cranwell, & Sinclair,
2016).

Figure 2: Sinclair Scale for female pattern baldness

lier, as early as their 30s or 40s. Male-pattern baldness and
female-pattern baldness are both hereditary conditions
that lead to more drastic hair loss than that which occurs
with normal aging (Shapiro, 1998).
For male pattern baldness, there is a receding hairline
and thinning hair on the crown of their heads. There are
28

Cause
Androgenetic alopecia is caused by both genetic and hormonal factors (Shapiro, 1998). Hair loss caused by androgenetic alopecia can be inherited from both the mother
and the father. The disease tends to run in families with
male androgenetic alopecia and having a close relative
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with patterned hair loss appears to be a risk factor for
developing the condition (Medline Plus, 2015). About
80% of the risk is inherited (Cranwell, & Sinclair, 2016).
There are a number of genetic factors that influence male
pattern baldness, but the main influencers are the body’s
production of androgens (Liang, et al., 2018). Androgens
are the male sex hormones, which are responsible for
various male characteristics such as body and beard hair,
muscle mass, bone growth, fat distribution throughout the
body, voice deepening, etc (Jewell, 2019). As the body tries
to encourage the development of male sexual characteristics during puberty, significant amounts of androgens are
produced (Liang, et al., 2018). Androgens in men are usually available in the form of testosterone, much of which
is converted to dihydroxy testosterone (DHT). DHT is a
naturally occurring by-product of testosterone. 5α−reductase, an enzyme in the hair follicle’s sebaceous (oil)
glands helps convert testosterone to DHT. This process
happens in both men and women, even though women
have less testosterone than men. In research studies,
about 10% of testosterone molecules are converted to
DHT by the enzyme 5α−reductase (Jewell, 2019). By
DHT binding to the scalp hair follicle androgen receptors
(AR), it causes androgenetic alopecia (Cranwell, & Sinclair,
2016). DHT is a far more potent hormone for hair growth
than testosterone due to its higher binding affinity and
lower dissociation constant with the androgen receptor
(French, et al., 1990). As DHT travels through your bloodstream, it can then bind to receptors on hair follicles on
your scalp, causing them to shrink and become less able
to support a healthy head of hair (Jewell, 2019).
A significant pathophysiological feature of androgenetic alopecia is the alteration of hair cycle development
and the miniaturization of the hair follicle (Cranwell &
Sinclair, 2016). Understanding the hair growth cycle helps
understand how DHT causes hair loss. The cycle includes
four phases: growing (anagen), transitional (catagen), resting (telogen) and shedding (exogen). Over time, DHT
accumulates in hair follicles, interfering with its growth
cycle. Known as miniaturization, DHT shrinks hair follicles, slowing the rate at which hair strands reproduce
by either shortening the growing phase or lengthening
the resting phase. With each subsequent life cycle, AGA
advances along with the destruction of follicles by DHT,
which causes hair to become thinner, brittle, and lighter in
color. A follicular pore ultimately remains empty because
the hair will not grow long enough to reach the surface of
the skin during the anagen phase. Eventually, the follicles
shut down and will no longer produce hair (Cranwell &
Sinclair, 2016).

Gene Factor of MPB
The main cause of male pattern hair loss is DHT. DHT
affects both the natural genetic predisposition to hair loss
as well as natural processes in your body that lead to
hair loss as you age. Proteins called androgen receptors
allow hormones such as testosterone and DHT to bind
to them. As a result, normal hormonal processes such
as hair growth occur. Depending on how the androgen
receptor gene (AR) is configured, some individuals are
more susceptible to the effects of DHT on scalp hair.
Therefore, having variations in the AR gene increases the
chances of experiencing MPHL (Jewell, 2019).
Treatments
Alopecia androgenetic is an androgen-dependent trait
determined primarily by genetics (Redler, et al., 2017). It is
characterized by the gradual conversion of terminal hairs
into indeterminate, with the help of the DHT hormone.
Both men and women are affected by this disease. In
order to treat androgenetic alopecia, there are only two
drugs that have been approved by the US Food and Drug
Administration (FDA) (Feinstein, 2020). The two drugs
increase hair length and diameter by modulating the hairgrowth cycle, although their mechanisms of action are
different. Both medications slow the rate of hair loss but
only partially reverse baldness, and must be taken continuously to maintain their effectiveness. AGA can also be
treated with oral dutasteride, ketoconazole, platelet-rich
plasma (PRP), low-level laser therapy, and hair transplantation (Dabek, et al., 2019).
Minoxidil
In today’s technologically advanced world, minoxidil can
be found as an oral drug, a topical cream, and a foam.
Minoxidil is used both by men and women who suffer
from pattern hair loss. It is a non-androgen hair-growth
stimulator, it promotes new hair growth by allowing
blood vessels in the scalp to carry nutrients to the affected hair follicles. Minoxidil does not stop DHT from
reaching the follicles. It is effective for many men because
it encourages hair growth and makes areas of the scalp
with thin hair look thicker, fuller, and less affected by hair
loss (Suchonwanit, et al., 2019).
Minoxidil was first introduced in the 1970s as an oral
medication to treat severe hypertension (Campese,
1981). A topical minoxidil formulation was developed as
a result of physicians observing hair growth in balding patients and generalized hypertrichosis in women after they
observed hair regrowth in male patients (Suchonwanit, et
al., 2019). According to Suchonwanit, the minoxidil 2%
solution was first made available to the public in 1986,
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followed by its 5% version in 1993.The US FDA approved
minoxidil brand-name Rogaine, at a maximum concentration of 5%, for over-the-counter use in 1996 (Goren &
Naccarato, 2018). A generic version is available by prescription in the form of oral tablets and over the counter
in the form of a topical liquid or foam.
Many studies have shown that minoxidil has been widely used since the early 1980s; however, the mechanisms
by which it promotes hair growth are not completely
understood (Suchonwanit, et al., 2019). The hair growth
that is caused by minoxidil has been attributed to various
theories. This molecule opens potassium channels, which
induces hyperpolarization of cellular membranes, as well as
acting as a vasodilator; it is hypothesized that by widening
blood vessels and opening potassium channels, it allows
more oxygen, blood, and nutrients to pass to the follicles. In
addition, in the telogen phase, hair follicles can shed, usually
shortly before they are replaced by new, thicker hair in the
anagen phase (Rossi, et al., 2012)
The effectiveness of topical minoxidil was investigated
in numerous clinical trials using different concentrations
and preparations. For men with AGA, 5% MS increased the
mean difference in hair density significantly compared to
2% MS or a placebo. Significantly more hair regrowth was
noted in the 5% MS group than in the 2% MS group at
week 48. FPHL results for both the 2% and the 5% MS
groups were promising. There were, however, more side
effects with 5% MS, including dermatitis, headaches, and hypertrichosis.Women are prescribed the 2% solution, while
men receive the 5%. It is preferred for women to use 2%
MS since hypertrichosis could be problematic for them,
having unwanted hair growth that can occur, resulting in
poor treatment compliance (Suchonwanit, et al., 2019).
Treatment of androgenetic alopecia with topical minoxidil has been demonstrated to be safe and effective. In
order for the hair to be maintained consistently, it must
be applied once or twice a day. (Rossi, et al., 2012). After
12 weeks of daily treatment, results should be visible, but
hair loss will return within four to six months if treatment
is discontinued (Dabek, et al., 2019). Usually, regrowth occurs at the vertex rather than in the frontal areas and it
is not observable for at least 4 months (Feinstein, 2020).
While complications are extremely rare, patients who use
minoxidil may experience symptoms such as pruritus, scaling of the scalp, skin irritation, orthostatic hypotension, and
erectile dysfunction (Dabek, et al., 2019). However, reports
show that the most common adverse reactions of the topical formulation are irritant and allergic contact dermatitis
on the scalp with symptoms like itching and scaling (Rossi,
Mari, et al., 2012). According to studies, several topical
solutions containing propylene glycol are known to cause
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allergic reactions, particularly if they contain galenic. When
using 2% minoxidil, the incidence is lower than with 5%
minoxidil. Propylene glycol (PG) or minoxidil itself can also
cause allergic contact dermatitis. It is important to conduct
a patch test to identify the cause. Minoxidil can cause an
allergic reaction, but it is rare. It is recommended to substitute butylene glycol, glycerin, or polysorbate if the patient
is allergic to PG. If the reaction does not resolve, minoxidil
foam (MF), which is PG-free, should be prescribed. In such
a circumstance, a minoxidil allergy should be suspected,
and all minoxidil preparations should be discontinued
(Friedman, et al., 2002).
Many patients who are prescribed topical minoxidil have
difficulties adhering to the treatment plan because it requires two applications a day, it causes undesirable hair
texture, and it causes scalp irritation (Randolph & Tosti,
2021). To address these concerns, a topical foam of minoxidil was developed that is free of propylene glycol.
A study comparing a minoxidil solution and minoxidil
foam was conducted. As a result, the US Food and Drug
Administration (FDA) has approved 5% MF for the treatment of both men and women who have AGA due to its
ability to deliver the active ingredient to the target site
and penetrate the drug easily with less irritation. A major
advantage of MF is that it dries quicker and spreads less
to the peripheral region. (Campese, 1981).
As an alternative to topical MS, another study was conducted on oral minoxidil. This was found to be an effective, safe, and well-tolerated treatment option for healthy
patients who had difficulty with topical formulations
(Randolph & Tosti, 2021). The benefit of topical minoxidil
is that it has greater patient compliance in addition to its
therapeutic properties. Studies recommend that woman
take less than 0.25 mg daily, while men should take at least
1.25 mg daily for maximum effect (Villani, et al., 2021).
In order to determine the most effective treatment protocol, including dosage and treatment duration, larger
randomized comparative studies should be conducted.
The evidence appears to suggest that minoxidil can be
used effectively to treat male pattern baldness.
Finasteride
FDA has approved only two drugs to treat hair loss and finasteride is one of them. It is an inhibitor of the enzyme 5α−
reductase that can potentially reduce male pattern baldness.The FDA approved finasteride for medical use in 1992
(Fischer & Ganellin, 2006). Patients with benign prostatic
hyperplasia were initially prescribed finasteride at a dose of
5mg daily under the brand names Proscar and Propecia. In
men, this medication is now used to treat benign prostatic
hyperplasia and hair loss. (Cranwell & Sinclair, 2016).
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Despite its name, finasteride is an antiandrogen because it inhibits 5α-reductase type II and III. As a result,
dihydrotestosterone (DHT) production drops by about
70% in the prostate gland and on the scalp. This is accomplished by finasteride binding to the 5-AR proteins
and preventing DHT from binding with them. Since DHT
cannot bind to your hair follicles, your hair follicles will
not shrink. (Cranwell & Sinclair, 2016).
An oral finasteride dose of 1 mg/day is recommended
to treat male pattern hair loss (Gormley, et al., 1990). By
taking this daily, it will reduce the scalp DHT by 64% and
serum DHT by 68%.The efficacy of finasteride in patients
with MAA was further demonstrated in a randomized,
double-blind, placebo-controlled twin study. Four out of
five subjects in the finasteride group had an increase in
hair count by month 12, while 44% of the placebo group
had decreased hair count. In the finasteride group, levels
of serum DHT were significantly lower, while placebo levels did not change significantly. (Cranwell & Sinclair, 2016).
The hair on the bitemporal and vertex regions of the
male scalp is particularly susceptible to high levels of circulating androgens, and it responds well to finasteride
oral treatment (Dabek, et al., 2019). It was also clinically
observed, that finasteride acts in both the front area and
the vertex, (Rossi, Mari, et al., 2012). On the vertex and
superior-frontal areas of the scalp, the finasteride group
showed significant improvement in hair growth, whereas
neither group showed improvements in hair growth on
the temporal or anterior hairline areas. Compared to
the minimal response over the temporal and anterior
hairline regions, this study shows the relative efficacy of
finasteride in protecting hair over the vertex and superior-frontal regions of the scalp (Cranwell & Sinclair, 2016).
A randomized controlled study using 5% topical minoxidil and 1 milligram of finasteride showed that finasteride
increased hair growth dramatically. The effectiveness of
finasteride is greater than that of minoxidil, but it comes
with its own side effects (Cranwell & Sinclair, 2016). The
tolerability of the placebo and finasteride receiving groups
was similar overall. In the group receiving finasteride, the
main difference between those who received finasteride
and those who did not was a higher percentage of sexual
function abnormalities (Waldstreicher, et al., 1997). The
sexual function disorders include libido and impotence,
and in severe cases, it may cause gynecomastia, pain in
the testicles, and inability to urinate (WebMD, 2021). In
both groups, there was a difference, but it was quite small,
only 3.8% in the placebo group and 2.1% in the finasteride
group. The majority of patients who reported sexual
problems during treatment were able to resolve those
problems despite continuing to take finasteride. Many of

those who withdrew from the trial due to sexual disorders reported that the problems resolved after discontinuing the drug (Waldstreicher, et al., 1997). Based on these
studies, it appears that men experience reduced hair
loss when taking finasteride. From this study, we see that
Finasteride causes hair regrowth by altering DHT levels,
which lends credence to the DHT theory of baldness.
Along with knowing the side effects, it is essential
not to use finasteride near pregnant or nursing women.
Dermatologically, the drug can be absorbed. It is not
recommended that pregnant or planning to become
pregnant women handle a tablet if the film coating has
been broken or if the tablet has been crushed. An infant
exposed to finasteride may develop abnormalities of the
genital area (WebMD, 2021).
In order to determine the most effective treatment
protocol, including dosage and treatment duration, larger
randomized comparative studies should be conducted. It
is well known that minoxidil is an effective treatment for
male pattern hair loss. However, it is less effective than
finasteride, but the advantage of using a topical solution is
that it is easily absorbed into the scalp. Since one needs to
use finasteride continuously to prevent further hair loss,
long-term studies of potential side effects are necessary.
Dutasteride
The FDA does not approve all drugs, but some of them
are potentially helpful medications. Dutasteride 0.5mg
dosage was approved by the FDA for the treatment of
benign prostatic hyperplasia while MAA uses are off-label.
The oral drug dutasteride may also be used for androgenetic alopecia, like finasteride. Approximately three times
as potent as finasteride in inhibiting the type II enzyme,
and 100 times as potent in inhibiting the type I enzyme,
this drug inhibits both types I and II 5-a reductase isoenzymes (Feinstein, 2020). In comparison, dutasteride
can decrease serum DHT by more than 90%, whereas
finasteride decreases it by 70%. Due to these properties, dutasteride makes a more promising candidate for
MPB treatment. Although dutasteride has more desirable
properties, relatively little research has been conducted
on its use in the treatment of MPB (Rafi & Katz, 2011).
During a phase II randomized placebo-controlled trial,
it was determined dutasteride had a stronger effect
than finasteride when it came to improving scalp hair
growth in men between the ages of 21 and 45. An observational phase II randomized placebo-controlled trial
of dutasteride and finasteride found that dutasteride was
more effective than finasteride at increasing scalp hair
growth, and 2.5mg dutasteride was more effective at enhancing growth in men aged 21 to 45. As compared to
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finasteride, it also increased hair growth. Hair count data
and clinical assessment data at 12 and 24 weeks were
used to demonstrate this (Rafi & Katz, 2011).
According to another recent randomized, double-blind,
placebo-controlled study, dutasteride 0.5mg/day significantly reduced hair loss progression in men with MAA.
According to another recent randomized, double-blind,
placebo-controlled study, dutasteride 0.5mg/day significantly reduced hair loss progression in men with MAA.
In a case report a woman who had failed to show any response to finasteride had success with dutasteride 0.5mg
(Cranwell & Sinclair, 2016).
Due to its ability to inhibit type I and type II five-alpha
reductase, it may be superior to finasteride at promoting hair growth in young males. Nevertheless, finasteride
is the preferred treatment for androgenetic alopecia.
Dihydrotestosterone plays important physiological roles
unrelated to androgenetic functions in finasteride, researchers stated. With dutasteride, side effects are more
likely than with finasteride. Among the possible side effects are decreased libido, impotence, and gynecomastia
(enlarged breasts). In patients treated with dutasteride,
the sperm count, and volume were reduced (Cranwell &
Sinclair, 2016).
Ketoconazole
Ketoconazole, pharmaceutically known as Nizoral, is an
antifungal agent with anti-inflammatory and anti-androgenic properties. It is available as a cream, solution and
shampoo for cutaneous fungal infections. It is commonly
known to be used as an anti-fungal shampoo to treat seborrheic dermatitis, dandruff, caused by excess Malassezia.
Besides KCZ treating fungus, there has been evidence
accumulated that shows ketoconazole being an effective
treatment for hair loss (Perez, 2004).
There is no clear explanation for why ketoconazole causes hair regrowth. It was found that Ketoconazole works by
interfering with DHT production, the hormone responsible for hair loss in men.When it is used topically on hair, it
works as a mild DHT antagonist compared to finasteride.
However, KCZ works as well as the FDA-approved topical
treatment minoxidil (Piérard-Franchimont, et al., 1998). It
is also found effective when used either alone or when
used with another FDA-approved hair loss treatment, like
finasteride or minoxidil (Perez, 2004).
There are different postulated theories of how KCZ
shampoo helps with hair loss It may be caused by an inflammatory reaction abutting the hair follicles (PiérardFranchimont, et al., 1998). Fields explains that every
individual’s head contains a fungus called Malassezia.
When there is too much buildup of Malassezia, it causes
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dandruff and it produces inflammation, resulting in flaking and itching and some hair loss (Fields, et al., 2020).
Interestingly, researchers have found that men with male
pattern baldness have more Malassezia on their heads
than the general population (Perez, 2004).
The ketoconazole anti-fungal shampoo gives relief from
dandruff and itching by killing the excess Malassezia (Huang,
et al., 2019). Malassezia may contribute to the process of
inflammation in androgenic alopecia, based on the data
presently available. A study was conducted to determine
how KCZ acted as an active against the microflora and
showed intrinsic anti-inflammatory activity that improved
alopecia. Researchers compared 2% KCZ shampoo to an
unmedicated shampoo with or without 2% minoxidil therapy in a study.There was an almost similar improvement in
hair density, size, and proportion of the anagen follicles by
both KCZ and minoxidil regimens, and there was a significant decrease in sebum levels by KCZ.To assess the clinical
significance of the results, a larger sample size is needed
(Piérard-Franchimont, et al., 1998).
According to Cranwell, W., and Sinclair, R., a study was
conducted showing that topical ketoconazole shampoo
increased hair growth in both humans and rodents.
Additionally, there was an increase in the diameter of
hair shafts in association with the agents. Researchers
found topical ketoconazole to be an effective adjunctive or alternative treatment for androgenetic alopecia
(Cranwell & Sinclair, 2016). Another study, conducted in
1998, found that ketoconazole shampoo increased hair
density as well as the proportion and size of hair follicles
(Piérard-Franchimont, et al., 1998).
Ketoconazole may cause irregular hair texture, discoloration, irritation, or pimple-like bumps on the scalp. In
addition, hair and scalp may be oily or dry. Ketoconazole
shampoo is only approved for treating seborrheic dermatitis of the scalp and dandruff. As an anti-hair loss treatment, the product cannot be advertised or marketed to
the general public. Further studies need to be conducted
to show the effectiveness of KCZ. It is also worth noting
that more research needs to be done on the mechanism
behind how hair growth is caused.There also needs to be
research to demonstrate whether taking ketoconazole
for an extended period is safe.
PRP Treatment
The growth factors and stimulatory mediators naturally
present in platelet-rich plasma (PRP) can be extracted
from whole blood for use in medicine. PRP therapy has
been used for decades for the stimulation of muscle, tendon, and ligament healing. A recent limited study suggests
that PRP can also be used as a standalone treatment
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for AGA with minimal side effects. This procedure uses
platelet-rich plasma, which can be found in your blood, to
promote hair growth on your scalp (Cranwell & Sinclair,
2016).
A study conducted in Spain in 2015 proved that plasma rich in growth factors, called PGRP, could be effective in treating androgenetic alopecia. In the study of
over 100 patients, PGRF was administered intradermally
twice a week for a total of four cycles. It was found that
the anagen follicle count significantly increased by 6.2%
compared with baseline, while telogen follicle count decreased by 5.1%. There were no adverse effects observed
in any of the patients (Cranwell & Sinclair, 2016).
Low-level Light Therapy
As an over-the-counter hair growth method, laser light
therapy, in particular a red-light hairbrush, is being marketed. The HairMax LaserComb® has been approved for
medical use by the FDA as a medical device. In this approval, safety has been emphasized rather than effectiveness, and the data necessary to demonstrate the safety
and effectiveness of medical devices differ considerably
from those needed for drugs (Feinstein, 2020).
An extensive study was published in 2014, which had
the largest sample size to date. The purpose of this double-blind, randomized, sham-controlled study was to examine 128 males and 141 females with pattern hair loss.
Researchers randomized participants to either receive a
sham or a real HairMax Lasercomb®. Over the course of
26 weeks, patients received three treatments per week,
with varying treatment times per day depending on the
model of Lasercomb®. This ensured that the total laser
dose remained the same across all models. Based on the
results, all LLLT-treated groups showed statistically significant improvement in hair density compared to their
sham counterparts. Although not all patients experienced
statistically significant results, most self-assessments of
hair loss condition and thickness showed improvement
after LLLT treatments. A number of adverse events
have been reported, including dry skin, pruritus, a warm
sensation, and scalp tenderness. The current study has
several strengths, including the large sample size, sham
device-controlled, double-blind design, as well as objective measurements and self-assessments by the subjects
(Darwin, et al., 2018).
In the case of androgenic alopecia, LLLT is a safe and
effective treatment option. In studies with similar treatment durations, oral finasteride and topical minoxidil
appear to be comparable in their hair growth efficacy.
In comparison with other AGA treatment options on
the market, LLLT has been shown to have no significant

side effects. The research suggests that the drug may be
effective when combined with minoxidil and finasteride,
as well as a primary treatment option. Patients who have
not reacted to finasteride or minoxidil and do not want
to undergo hair transplantation may benefit from the
LLLT. The device is safe and easy to use, and it does not
leave any residue on the scalp. In order to determine the
optimal wavelength and intensity of LLLT as a treatment
for androgenic alopecia, further research is needed. In addition, further study is required to understand the physiology and mechanism of LLLT for hair regrowth (Darwin,
et al., 2018).
Hair transplant
Surgical hair transplants are reserved for individuals who
do not respond to topical minoxidil and/or oral finasteride, or who cannot tolerate their risks. Individuals with
very little hair may not be recommended to have a hair
transplant. During a hair transplant, hair from the occipital scalp is removed and re-implanted into the bald vertex
and frontal scalp. It has only been in the last few years
that modern grafting techniques have permitted grafts to
survive reliably with greater than 90% survival. The two
prerequisites for the procedure are the stabilization of
the hair loss with medical treatment as well as a healthy
population of donor hair in the area of occipital hair
(Cranwell & Sinclair, 2016).
Discussion
Based on the research, DHT is a major cause of male
pattern hair loss, caused both by a genetic predisposition
to hair loss as well as by natural changes in the body that
causes hair loss as one ages. Plenty of hair loss treatments
addressing DHT are available and reducing hair loss may
make us feel more confident about our appearance in
our everyday life. It is still best to consult a doctor before
beginning any treatment, since not all treatments are safe
or effective for everyone.
Conclusion
Having androgenetic alopecia is distressing for many men
and women, and an increasing number of men and women
are pursuing treatment to prevent and reverse the process. It has been found that there are medications that can
slow or stop hair loss, and therefore, we may conclude
that androgenetic alopecia can be managed. Additionally,
it is concluded that drugs used to treat AGA are only
effective for so long as they are administered. This means
hair loss cannot be cured. In order to find a cure for hair
loss, we need a comprehensive theory that explains the
mechanism.
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